- Home
- MRNS vs BLRX Comparison
MRNS vs BLRX Comparison
Compare MRNS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- BLRX
- Stock Information
- Founded
- MRNS 2003
- BLRX 2003
- Country
- MRNS United States
- BLRX Israel
- Employees
- MRNS N/A
- BLRX N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MRNS Health Care
- BLRX Health Care
- Exchange
- MRNS Nasdaq
- BLRX Nasdaq
- Market Cap
- MRNS 104.7M
- BLRX 54.1M
- IPO Year
- MRNS 2014
- BLRX 2011
- Fundamental
- Price
- MRNS $1.74
- BLRX $0.46
- Analyst Decision
- MRNS Buy
- BLRX Strong Buy
- Analyst Count
- MRNS 9
- BLRX 2
- Target Price
- MRNS $9.75
- BLRX $11.50
- AVG Volume (30 Days)
- MRNS 751.9K
- BLRX 341.0K
- Earning Date
- MRNS 11-05-2024
- BLRX 11-18-2024
- Dividend Yield
- MRNS N/A
- BLRX N/A
- EPS Growth
- MRNS N/A
- BLRX N/A
- EPS
- MRNS N/A
- BLRX N/A
- Revenue
- MRNS $30,263,000.00
- BLRX $17,048,000.00
- Revenue This Year
- MRNS $21.18
- BLRX N/A
- Revenue Next Year
- MRNS $56.42
- BLRX N/A
- P/E Ratio
- MRNS N/A
- BLRX N/A
- Revenue Growth
- MRNS 16.56
- BLRX N/A
- 52 Week Low
- MRNS $1.05
- BLRX $0.43
- 52 Week High
- MRNS $11.26
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- MRNS 54.04
- BLRX 35.07
- Support Level
- MRNS $1.73
- BLRX $0.43
- Resistance Level
- MRNS $1.83
- BLRX $0.50
- Average True Range (ATR)
- MRNS 0.11
- BLRX 0.06
- MACD
- MRNS -0.01
- BLRX -0.00
- Stochastic Oscillator
- MRNS 46.15
- BLRX 13.33
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.